U.S. regulator is reviewing Abbott's fast COVID test after studies raise accuracy concerns

(Reuters) - The U.S. Food and Drug Administration said on Thursday that Abbott Laboratories’ speedy coronavirus test, which can deliver results within minutes and is used at the White House, could potentially be inaccurate but can still be used to test patients.

The regulator said in a statement that early data about the Abbott ID Now test suggested it could produce potentially inaccurate results, particularly by failing to detect people who have the illness.